CoChat

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer

Open access
Yarchoan, Mark, Myzak, Melinda C., Johnson, Burles A., De Jesus-Acosta, Ana, Le, Dung T., Jaffee, Elizabeth M., Azad, Nilofer S., Donehower, Ross C., Zheng, Lei, Oberstein, Paul E., Fine, Robert L., Laheru, Daniel A., Goggins, Michael · 2017 · Oncotarget
Cited by 77

The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.

Abstract

// Mark Yarchoan 1 , Melinda C. Myzak 1 , Burles A. Johnson III 1 , Ana De Jesus-Acosta 1 , Dung T. Le 1 , Elizabeth M. Jaffee 1 , Nilofer S. Azad 1 , Ross C. Donehower 1 , Lei Zheng 1 , Paul E. Oberstein 2 , Robert L. Fine 2 , Daniel A. Laheru 1 and Michael Goggins 1 1 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA 2 Columbia University Medical Center, New York, NY, USA Correspondence to: Michael Goggins, email: mgoggins@jhmi.edu Keywords: olaparib, pancreatic cancer, BRCA2, irinotecan, cisplatin Received: February 24, 2016 Accepted: March 13, 2017 Published: April 19, 2017 ABSTRACT Background: Olaparib is an oral inhibitor of polyadenosine 5’-diphosphoribose polymerization (PARP) that has previously shown signs of activity in patients with BRCA mutations and pancreatic ductal adenocarcinoma (PDAC). Patients and Methods: In this phase 1 dose-escalation trial in patients with unresectable PDAC, we determined the maximum tolerated dose (MTD) of olaparib (tablet formulation) in combination with irinotecan 70 mg/m 2 on days 1 and 8 and cisplatin 25 mg/m 2 on days 1 and 8 of a 28-day cycle (olaparib plus IC). We then studied the safety and tolerability of adding mitomycin C 5 mg/m 2 on day 1 to this regimen (olaparib plus ICM). Results: 18 patients with unresectable PDAC were enrolled. The MTD of olaparib plus IC was olaparib 100 mg twice-daily on days 1 and 8. The addition of mitomycin C to this dose level was not tolerated. Grade ≥3 drug-related adverse events (AEs) were encountered in 16 patients (89%). The most common grade ≥3 drug-related toxicities included neutropenia (89%), lymphopenia (72%), and anemia (22%). Two patients (11%), both of whom had remained on study for more than 12 cycles, developed drug-related myelodysplastic syndrome (MDS). The objective response rate (ORR) for all evaluable patients was 23%. One patient who carried a deleterious germline BRCA2 mutation had a durable clinical response lasting more than four years, but died from complications of treatment-related MDS. Conclusions: Olaparib had substantial toxicity when combined with IC or ICM in patients with PDAC, and this treatment combination did not have an acceptable risk/benefit profile for further study. However, durable clinical responses were observed in a subset of patients and further clinical investigation of PARP inhibitors in PDAC is warranted. Trial registration : This clinical trial was registered on ClinicalTrials.gov as NCT01296763.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.17237

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 11 references

Cited by

Metadata

Authors
Yarchoan, M., Myzak, M. C., Johnson, B. A., De Jesus-Acosta, A., Le, D. T., Jaffee, E. M., Azad, N. S., Donehower, R. C., Zheng, L., Oberstein, P. E., Fine, R. L., Laheru, D. A., & Goggins, M.
Venue
Oncotarget
Published
2017-04-19
Volume
8
Issue
27
Pages
44073-44081
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2606436364
Cited by
77
References
11
FWCI
3.77
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.